The observed shedding of the CFA/I positive ACAM2025 vaccine strain after immunization and the vaccine-induced anti-CFA/I IgA ALS response (≥3-fold increase over baseline) suggest a role for ant-CFA/I immunity as a marker for longer term protection against H10407 challenge. This evidence concerns the gene CD79A and amyotrophic lateral sclerosis.